The expression of PERK, p-PERK, ATF4, and Beclin1 decreased in ORMDL3-silenced HCC cells after sorafenib treatment, suggesting that ORMDL3 silencing can inhibit the expression of PERK, p-PERK, ATF4, and Beclin1 proteins (Fig. 5A, B). This evidence concerns the gene ATF4 and hepatocellular carcinoma.